We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 8 of 1325 for:    ALA

Evaluation of Safety and Efficacy of BF-200 ALA for the Treatment of Actinic Keratosis With Photodynamic Therapy

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT02799069
Recruitment Status : Completed
First Posted : June 14, 2016
Results First Posted : March 23, 2017
Last Update Posted : April 28, 2017
Sponsor:
Collaborator:
Accovion GmbH
Information provided by (Responsible Party):
Biofrontera Bioscience GmbH

Brief Summary:
The aim of the study is to evaluate the non-inferiority of BF-200 ALA (Ameluz) in the treatment of actinic keratosis (AK) with photodynamic therapy (PDT) compared to Metvix.

Condition or disease Intervention/treatment Phase
Actinic Keratosis Drug: BF-200 ALA Drug: MAL Cream Drug: Vehicle Phase 3

Detailed Description:
This was a randomized, observer-blind, multinational, comparator and placebo-controlled parallel group, (3:3:1 ratio) study to compare the efficacy and safety of BF-200 ALA with the comparator Metvix® (methyl-[5-amino-4-oxopentanoate]) and placebo, for the treatment of AK with PDT.

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 571 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single (Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Randomized, Observer Blind, Multinational Phase III Study to Evaluate the Safety and Efficacy of a Nanoemulsion Gel Formulation BF-200 ALA, in Comparison With Metvix® and Placebo, for the Treatment of Actinic Keratosis With PDT
Study Start Date : April 2008
Primary Completion Date : August 2009
Study Completion Date : August 2009


Arm Intervention/treatment
Active Comparator: BF-200 ALA
Topical application of BF-200 ALA gel containing 78 mg/g 5-aminolevulinic acid (ALA). Application of a 1 mm thick layer covering each lesion and a 0.5 cm to 1 cm surrounding margin.
Drug: BF-200 ALA
topical treatment for photodynamic therapy combining drug application and after a 3 h incubation subsequent illumination with a broad or narrow spectrum light source.
Other Name: Ameluz
Active Comparator: MAL Cream
Topical application of MAL cream (Metvix) containing 160 mg/g methyl-aminolevulinate (MAL). Application of a 1 mm thick layer covering each lesion and a 0.5 cm to 1 cm surrounding margin.
Drug: MAL Cream
topical treatment for photodynamic therapy combining drug application and after a 3 h incubation subsequent illumination with a broad or narrow spectrum light source.
Other Names:
  • Metvix
  • Metvixia
Placebo Comparator: Vehicle
Topical application of matched Placebo to BF-200 ALA gel (without containing active ingredient) ). Application of a 1 mm thick layer covering each lesion and a 0.5 cm to 1 cm surrounding margin.
Drug: Vehicle
topical treatment for photodynamic therapy combining vehicle application and after a 3 h incubation subsequent illumination with a broad or narrow spectrum light source.
Other Name: matched placebo to BF-200 ALA gel



Primary Outcome Measures :
  1. Percentage of Participants With Complete Response 12 Weeks After the Last Photodynamic Therapy (PDT), ITT [ Time Frame: 12 weeks after the last PDT, up to 24 weeks after the first treatment ]

    An overall complete responder was defined as a subject in whom all treated lesions were cleared (all lesions showing complete remission) 12 weeks after the last PDT.

    The outcome measure considered complete responders who were completely cleared 12 weeks after the first PDT and responders who were completely cleared 12 weeks after the second PDT if a re-treatment was necessary (in case of partial- or non-responding lesions 12 weeks after the first PDT)


  2. Percentage of Participants With Complete Response 12 Weeks After the Last Photodynamic Therapy (PDT), PP [ Time Frame: 12 weeks after the last PDT, up to 24 weeks after the first treatment ]

    An overall complete responder was defined as a subject in whom all treated lesions were cleared (all lesions showing complete remission) 12 weeks after the last PDT.

    The outcome measure considered complete responders who were completely cleared 12 weeks after the first PDT and responders who were completely cleared 12 weeks after the second PDT if a re-treatment was necessary (in case of partial- or non-responding lesions 12 weeks after the first PDT)


  3. Percentage of Participants With Complete Response 12 Weeks After the Last Photodynamic Therapy (PDT) Illuminated With Narrow Spectrum Devices Only [ Time Frame: 12 weeks after the last PDT, up to 24 weeks after the first treatment ]

    Subgroup analysis of patients treated with a narrow spectrum device for PDT Illumination (~630 nm).

    An overall complete responder was defined as a subject in whom all treated lesions were cleared (all lesions showing complete remission) 12 weeks after the last PDT.

    The outcome measure considered complete responders who were completely cleared 12 weeks after the first PDT and responders who were completely cleared 12 weeks after the second PDT if a re-treatment was necessary (in case of partial- or non-responding lesions 12 weeks after the first PDT)



Secondary Outcome Measures :
  1. Percentage of Participants With Complete Response 3-4 Weeks After First Photodynamic Therapy (PDT) [ Time Frame: 3-4 weeks after the first PDT ]
    A complete responder was defined as a subject in whom all treated lesions were cleared (all lesions showing complete remission) at 3-4 weeks after the first PDT.

  2. Percentage of Participants With Complete Response 12 Weeks After First Photodynamic Therapy (PDT) [ Time Frame: 12 weeks after the first PDT ]
    A complete responder was defined as a subject in whom all treated lesions were cleared (all lesions showing complete remission) at 12 weeks after the first PDT.

  3. Percentage of Participants With Complete Response 3-4 Weeks After the Second Photodynamic Therapy (PDT) [ Time Frame: 3-4 weeks after the second PDT, 15-16 weeks after first treatment ]
    A complete responder was defined as a subject in whom all treated lesions were cleared (all lesions showing complete remission) at 3-4 weeks after the second PDT. A second PDT was applied in case partial- or non-responding lesions remained 12 weeks after the first PDT.

  4. Percentage of Participants With Complete Response 12 Weeks After Second Photodynamic Therapy (PDT) [ Time Frame: 12 weeks after the second PDT, 24 weeks after first treatment ]
    A complete responder was defined as a subject in whom all treated lesions were cleared (all lesions showing complete remission) at 12 weeks after the second PDT. A second PDT was applied in case partial- or non-responding lesions remained 12 weeks after the first PDT.

  5. Percentage of Participants With Complete Response 3-4 Weeks After Last Photodynamic Therapy (PDT) [ Time Frame: 3-4 weeks after the last PDT, up to 16 weeks after the first treatment ]
    A complete responder at week 3-4 after treatment was defined as a subject in whom all treated lesions were cleared (all lesions showing complete remission). This outcome measure considered patients who were completely cleared at 3-4 weeks after the last PDT which included complete responders 3-4 weeks after the first and complete responders 3-4 weeks after the second PDT ( a second PDT was applied in case of remaining lesions 12 weeks after the first PDT).

  6. Percentage of Participants With Partial Response at 3-4 Weeks After First Photodynamic Therapy (PDT) [ Time Frame: 3-4 weeks after the first PDT ]
    A partial responder was defined as a subject in whom at least 75% of the treated lesions were cleared (lesions showing complete remission). This outcome measure considers partial responders at 3-4 weeks after the first PDT.

  7. Percentage of Participants With Partial Response at 12 Weeks After the First Photodynamic Therapy (PDT) [ Time Frame: 12 weeks after the first PDT ]
    A partial responder was defined as a subject in whom at least 75% of the treated lesions were cleared (lesions showing complete remission). This outcome measure considers partial responders at 12 weeks after the first PDT.

  8. Percentage of Participants With Partial Response at 3-4 Weeks After the Second Photodynamic Therapy (PDT) [ Time Frame: 3-4 weeks after the second PDT, 15-16 weeks after first treatment ]

    A partial responder was defined as a subject in whom at least 75% of the treated lesions were cleared (lesions showing complete remission). This outcome measure considers partial responders at 3-4 weeks after the second PDT.

    A second PDT was applied in case of partial- or non-responding lesions 12 weeks after the first PDT.


  9. Percentage of Participants With Partial Response at 12 Weeks After the Second Photodynamic Therapy (PDT) [ Time Frame: 12 weeks after the second PDT, 24 weeks after first treatment ]

    A partial responder was defined as a subject in whom at least 75% of the treated lesions were cleared (lesions showing complete remission). This outcome measure considers partial responders at 12 weeks after the second PDT.

    A second PDT was applied in case of partial- or non-responding lesions 12 weeks after the first PDT.


  10. Percentage of Participants With Partial Response at 3-4 Weeks After Last Photodynamic Therapy (PDT) [ Time Frame: 3-4 weeks after the last PDT, up to 16 weeks after the first treatment ]

    A partial responder was defined as a subject in whom at least 75% of the treated lesions were cleared (lesions showing complete remission). This outcome measure considers partial responders at 3-4 weeks after last PDT.

    The outcome measure combined partial responders with at least 75% of lesions cleared at 3-4 weeks after the first PDT or after the second PDT (a second PDT was applied in case of partial- or non-responding lesions 12 weeks after the first PDT).


  11. Percentage of Participants With Partial Response at 12 Weeks After Last Photodynamic Therapy (PDT) [ Time Frame: 12 weeks after the last PDT, up to 24 weeks after first treatment ]

    A partial responder was defined as a subject in whom at least 75% of the treated lesions were cleared (lesions showing complete remission). This outcome measure considers partial responders at 12 weeks after last PDT.

    The outcome measure combined partial responders with at least 75% of lesions cleared at 12 weeks after the first PDT and after the second PDT (a second PDT was applied in case of partial- or non-responding lesions 12 weeks after the first PDT) .


  12. Complete Lesion Response Rate 3-4 Weeks After First Photodynamic Therapy (PDT) [ Time Frame: 3-4 weeks after the first PDT ]
    Completely cleared individual lesions as defined at 3-4 weeks after first photodynamic therapy (PDT)

  13. Complete Lesion Response Rate 12 Weeks After First Photodynamic Therapy (PDT) [ Time Frame: 12 weeks after the first PDT ]
    Completely cleared individual lesions as defined at 12 weeks after the first photodynamic therapy (PDT).

  14. Complete Lesion Response Rate 3-4 Weeks After the Second Photodynamic Therapy (PDT) [ Time Frame: 3-4 weeks after the second PDT, 15-16 weeks after first treatment ]
    Completely cleared individual lesions as defined at 3-4 weeks after the second PDT. A second PDT was applied in case the individual lesion showed no or partial response12 weeks after first PDT.

  15. Complete Lesion Response Rate 12 Weeks After Second PDT [ Time Frame: 12 weeks after the second PDT, 24 weeks after first treatment ]
    Completely cleared individual lesions as defined at 12 weeks after second PDT. A second PDT was applied in case the individual lesion showed no or partial response 12 weeks after first PDT.

  16. Complete Lesion Response Rate 3-4 Weeks After Last Photodynamic Therapy (PDT) [ Time Frame: 3-4 weeks after the last PDT, up to 16 weeks after first treatment ]
    Completely cleared individual lesions defined at 3-4 weeks after the last PDT comprising of completely cleared individual lesions 3-4 weeks after the first and after the second PDT (a second PDT was applied in case lesions show no or partial response 12 weeks after the first PDT).

  17. Complete Lesion Response Rate 12 Weeks After Last Photodynamic Therapy (PDT) [ Time Frame: 12 weeks after the last PDT, up to 24 weeks after first treatment ]
    Completely cleared individual lesions 12 weeks after last PDT comprising of completely cleared individual lesions 12 weeks after the first or second PDT (a second PDT was applied in case individual lesions show no or partial response 12 weeks after first PDT).

  18. Complete Lesion Response Rates 12 Weeks After Last Photodynamic Therapy (PDT) Illuminated With Narrow Spectrum Devices Only [ Time Frame: up to 12 weeks after the last PDT, up to 24 weeks after first treatment ]

    Completely cleared individual lesions 12 weeks after last PDT comprising of individual cleared lesions 12 weeks after the first or second PDT. A second PDT was applied in case individual lesion showed no or partial response 12 weeks after the first PDT.

    Lesions were illuminated during photodynamic therapy with narrow spectrum devices only (~630 nm).


  19. Change From Baseline in Total Lesion Area 3-4 Weeks After the First Photodynamic Therapy (PDT) [ Time Frame: 3-4 weeks after the first PDT ]
    Percentage of change from baseline in the lesion area of all treated lesions per subject (summation of sizes of all treated lesions) assessed at 3-4 weeks after the first PDT.

  20. Change From Baseline in Total Lesion Area 12 Weeks After the First Photodynamic Therapy (PDT) [ Time Frame: 12 weeks after the first PDT ]
    the change from baseline in the lesion area of all treated lesions per subject (summation of sizes of all treated lesions) assessed 12 weeks after the first PDT.

  21. Change From Baseline in Total Lesion Area 3-4 Weeks After the Second Photodynamic Therapy (PDT) [ Time Frame: 3-4 weeks after the second PDT, 15-16 weeks after first treatment ]
    the change from baseline in the lesion area of all treated lesions per subject (summation of sizes of all treated lesions) assessed 3-4 weeks after the second PDT. A second PDT was applied in case of non or partially responding lesions 12 weeks after first PDT.

  22. Change From Baseline in Total Lesion Area 12 Weeks After Second Photodynamic Therapy (PDT) [ Time Frame: 12 weeks after the second PDT, 24 after first treatment ]
    the change from baseline in the lesion area of all treated lesions per subject (summation of sizes of all treated lesions) assessed 12 weeks after the second PDT. A second PDT was applied in case of non- or partially responding lesions 12 weeks after first PDT.

  23. Change From Baseline in Total Lesion Area 3-4 Weeks After Last Photodynamic Therapy (PDT) [ Time Frame: 3-4 weeks after the last PDT, up to 16 weeks after the first treatment ]
    the change from baseline in the lesion area of all treated lesions per subject (summation of sizes of all treated lesions) assessed at 3-4 weeks after last PDT, combining the changes from baseline in total lesion area of subjects 3-4 weeks after first PDT and second PDT (a second PDT was applied for subjects who showed non- or partially responding lesions 12 weeks after the first PDT).

  24. Change From Baseline in Total Lesion Area 12 Weeks After Last Photodynamic Therapy (PDT) [ Time Frame: 12 weeks after the last PDT, up to 24 weeks after the first treatment ]
    the change from baseline in the lesion area of all treated lesions per subject (summation of sizes of all treated lesions) assessed at 12 weeks after last PDT, combining the changes from baseline in total lesion area at 12 weeks after the first PDT and at 12 weeks after the second PDT (a second PDT was applied to subjects with non- or partially responding lesions 12 weeks after the first PDT).

  25. Overall Cosmetic Outcome of the Treated Skin 12 Weeks After Last Photodynamic Therapy (PDT) Compared to Baseline [ Time Frame: 12 weeks after the last PDT, up to 24 weeks after first treatment ]
    The cosmetic outcome 12 weeks after the last PDT (12 weeks after 1st PDT for subjects who are completely cleared at this time point, 12 weeks after 2nd PDT for subjects retreated due to remaining lesions 12 weeks after 1st PDT) will be calculated on the basis of the skin quality assessment (skin surface, hyperpigmentation, hypopigmentation, mottled or irregular pigmentation, degree of scarring, and atrophy) upon visual examination (scale: 0= none, 1= mild, 2= moderate, 3=severe). The cosmetic outcome is rated as very good if the sum score of the previously mentioned ratings (all ratings for each sign added up) has improved by at least 2 points as compared to baseline; as good if the sum score has improved by at least 1 point as compared to baseline; as satisfactory if the sum score is identical to the one at baseline; as unsatisfactory if the sum score has worsened by 1 point compared to baseline and as impaired if the sum score has worsened by at least 2 points compared to baseline.

  26. Local Skin Reactions During First Photodynamic Therapy (PDT-1) [ Time Frame: during PDT treatment [3 h - 4 h ] ]
    Local skin reactions in the treatment area as assessed by the investigator during the first PDT (PDT-1)

  27. Local Skin Reactions During Second Photodynamic Therapy (PDT-2) for Retreated Subjects [ Time Frame: during PDT treatment [3 h - 4 h ] ]
    Local skin reactions in the treatment area as assessed by the investigator during PDT-2; only applicable for subjects who were retreated with a second PDT due to remaining lesions 12 weeks after the first PDT (subjects with data).

  28. Local Discomfort During First Photodynamic Therapy (PDT-1) [ Time Frame: during PDT treatment [3 h - 4 h ] ]
    Local discomfort reported by the patients during Illumination of first PDT (PDT1)

  29. Local Discomfort During Second Photodynamic Therapy (PDT-2) for Retreated Subjects [ Time Frame: during PDT treatment [3 h - 4 h ] ]
    Local discomfort reported by the patients during Illumination phase of retreatment (PDT-2); only applicable for subjects who received a retreatment (PDT-2) due to remaining lesions 12 weeks after the first treatment (PDT-1) (subjects with data)

  30. Local Discomfort - Pain During First Photodynamic Therapy (PDT-1) [ Time Frame: during PDT treatment [3 h - 4 h ] ]
    Pain (11-point numeric rating scale) by PDT Session; Overall (If both areas have been treated, maximum intensity over both areas is used for analysis.) Patients assessed the pain experienced during PDT using an 11-point numeric rating pain scale (NRPS) ranging from 0 (no pain at all) to 10 (worst possible pain). This score reflects the patient's maximum pain during PDT. This outcome measure shows pain score after the first PDT.

  31. Local Discomfort - Pain During Second Photodynamic Therapy (PDT-2) for Retreated Subjects [ Time Frame: during PDT treatment [3 h - 4 h ] ]

    Pain (11-point numeric rating scale) by PDT Session; Overall (If both areas have been treated, maximum intensity over both areas is used for analysis.) Patients assessed the pain experienced during PDT using an 11-point numeric rating pain scale (NRPS) ranging from 0 (no pain at all) to 10 (worst possible pain). This score reflects the patient's maximum pain during PDT.

    Only applicable for subjects who received a retreatment (PDT-2) due to remaining lesions 12 weeks after the first treatment (PDT-1) (subjects with data)


  32. Adverse Reactions [ Time Frame: up to 12 weeks after the last PDT, up to 24 weeks after first treatment ]

    Adverse reactions are Treatment-Emergent Adverse Events considered at least possibly related to the treatment with the randomized investigational medicinal products; Adverse reactions are shown with a frequency cut off of >=5%.

    TEAEs are considered from subjects who received only one PDT or subjects who received 2 PDTs (initial Treatment (PDT-1) and retreatment (PDT-2) due to remaining lesions 12 weeks after first photodynamic therapy.

    The safety set consists of all patients treated at least once with investigational product. Treatment with investigational product consists of application of study drug followed by illumination. This excludes one patient from the safety set; for this patient the investigational product was applied on the skin but it was not illuminated. Patients are treated according to actual treatment.




Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years to 85 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Main Inclusion Criteria:

  • Written informed consent.
  • Men and women between 18 and 85 years of age.
  • 4-8 AK lesions of 0.5 to 1.5 cm diameter of mild to moderate intensity (Olsen grade 1 and 2) in the face and/or on the bald scalp. Lesions on the eyes, nostrils, ears and mouth were not considered for treatment during the planned study.
  • Target AK lesions were to be discrete and quantifiable; adjacent AK lesions were to show a minimum distance of 1.0 cm from one another.
  • Confirmation of AK by biopsy taken at screening.
  • Free of significant physical abnormalities (e.g., tattoos, dermatoses) in the potential treatment region that could have caused difficulty with examination or final evaluation.
  • Willingness to stop the use of moisturizers and any other topical treatments within the treatment region.
  • Good general health condition.
  • Healthy subjects and subjects with clinically stable medical conditions including, but not limited to the following diseases (controlled hypertension, diabetes mellitus type II, hypercholesterolemia, osteoarthritis) were permitted to be included in the study if the medication taken for the treatment of the disease did not match an exclusion criterion or was not specified as prohibited concomitant medication.
  • No extensive sunbathing or solarium use during the trial.
  • Negative pregnancy test at screening.

Main exclusion criteria:

  • Known hypersensitivity to BF-200 ALA, MAL (methyl-aminolevulinic acid) and/or any of the ingredients of the formulations
  • Clinically significant medical conditions (tumor disease etc.) making implementation of the protocol or interpretation of the study results difficult
  • Presence of photodermatoses
  • Presence of other tumors in the treatment areas within the last 4 weeks
  • Start of treatment with phototoxic or photoallergic drugs within 8 weeks prior to screening
  • Current treatment with immunosuppression therapy
  • Hypersensitivity to porphyrins
  • Presence of porphyria
  • Presence of inherited or acquired coagulation defect
  • Any topical treatment within the treatment area within 12 weeks before PDT1 (first PDT Treatment)
  • Topical treatment with ALA or MAL outside the treatment area during participation in the study
  • None of the specified systemic treatments within the designated period before PDT1

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02799069


Sponsors and Collaborators
Biofrontera Bioscience GmbH
Accovion GmbH
Investigators
Principal Investigator: Thomas Dirschka, Prof. Dr. Akademische Lehrpraxis der Universität Witten-Herdecke Heinz-Fangman-Straße 57 42287 Wuppertal

Publications:
Responsible Party: Biofrontera Bioscience GmbH
ClinicalTrials.gov Identifier: NCT02799069     History of Changes
Other Study ID Numbers: ALA-AK-CT002
First Posted: June 14, 2016    Key Record Dates
Results First Posted: March 23, 2017
Last Update Posted: April 28, 2017
Last Verified: March 2017
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Additional relevant MeSH terms:
Keratosis
Keratosis, Actinic
Skin Diseases
Precancerous Conditions
Neoplasms
Methyl 5-aminolevulinate
Aminolevulinic Acid
Photosensitizing Agents
Dermatologic Agents